• Lifecore Biomedical posted a net loss of USD 15 million, or USD 0.43 per diluted share, for first-quarter 2026.
• Revenue dropped 34% to USD 23.2 million, while gross margin fell 8.8 percentage points to 19%.
• Adjusted EBITDA slid to USD 1 million from USD 5.7 million in the prior-year quarter.
• Operating expenses fell 52% to USD 9.1 million, while operating cash flow totaled USD 4.7 million with free cash flow of USD 3.6 million.
• Signed three new commercial site transfer programs, reaffirmed 2026 outlook for revenue of USD 120 million to USD 125 million with adjusted EBITDA of USD 20.5 million to USD 25 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifecore Biomedical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605060705PRIMZONEFULLFEED9714011) on May 06, 2026, and is solely responsible for the information contained therein.